Matrix Metalloproteinase Family Gene Polymorphisms and Lung Cancer Susceptibility: an Updated Meta-analysis

Overview

Journal J Thorac Dis

Publisher AME Publishing Company

Specialty Pulmonary Medicine

Date 2020 Apr 11

PMID 32274101

Citations 5

Authors

Xiaoliang Li

Caiyang Liu

Ran Ran

Gaohua Liu

Yanhui Yang

Wenzhuo Zhao

Xiaoyang Xie

Ji Li

Affiliations

Soon will be listed here.

Abstract

Background: Many studies have investigated the association between matrix metalloproteinase polymorphisms and lung cancer susceptibility. However, the results are still controversial. To clarify these associations, we conducted a meta-analysis.

Methods: A systematic search of studies was conducted in PubMed, Embase, and China National Knowledge Infrastructure. Overall and subgroup analysis stratified by ethnicity was conducted. OR with 95% CI was used to assess the strength of the association. Furthermore, false-positive report probability (FPRP) tests were also performed for associations obtained in this meta-analysis.

Results: Twenty-four studies, including 10,099 cases and 9,395 controls, were analyzed. Nine polymorphisms were reported. For MMP1 -1607 1G/2G and MMP7 -181 A/G, increased lung cancer risk was found in Asians. For MMP2 -1306 C/T and MMP2 -735 C/T, decreased lung cancer risk was found in both "diverse populations" and Asians. For MMP9 -1562, C/T decreased lung cancer risk was found in both "diverse populations" and Caucasians. For MMP13 -77A/G, the A/G genotype decreased lung cancer risk in Asians. However, only associations between MMP1 -1607 1G/2G, MMP2 -1306 C/T, MMP2 -735 C/T, and MMP7 -181 A/G and lung cancer risk were considered noteworthy according to FPRP tests. There was no association between MMP3 -1171 5A/6A, MMP9 R279Q, and MMP12 -82A/G and lung cancer risk.

Conclusions: Our meta-analysis suggested that MMP1 -1607 1G/2G and MMP7 -181 A/G were risk factors for lung cancer, while MMP2 -1306 C/T, MMP2 -735 C/T, MMP9 -1562 C/T, and MMP13 -77A/G might be protective factors. However, results for MMP9 -1562 C/T and MMP13 -77A/G should be interpreted with caution due to the probability of false-positive reports.

Citing Articles

Investigation of the Roles of MTHFR (C677T and A1298C) and MMP-2 (-1306C>T ) Variations in Bladder Cancer Development.

Alkanli N, Ay A Urol Res Pract. 2023; 49(1):33-39.

PMID: 37877836 PMC: 10081108. DOI: 10.5152/tud.2023.22185.

The multifaceted roles of matrix metalloproteinases in lung cancer.

Wei C Front Oncol. 2023; 13:1195426.

PMID: 37766868 PMC: 10520958. DOI: 10.3389/fonc.2023.1195426.

Analysis of -735C/T (rs2285053) and -1562C/T (rs3918242) Polymorphisms in the Risk Assessment of Developing Lung Cancer.

Wadowska K, Blasiak P, Rzechonek A, Sliwinska-Mosson M Int J Mol Sci. 2023; 24(13).

PMID: 37445754 PMC: 10341518. DOI: 10.3390/ijms241310576.

Overexpression of TWF1 promotes lung adenocarcinoma progression and is associated with poor prognosis in cancer patients through the MMP1 signaling pathway.

Zhai K, Jiang N, Wen J, Zhang X, Liu T, Long K J Thorac Dis. 2023; 15(5):2644-2658.

PMID: 37324107 PMC: 10267903. DOI: 10.21037/jtd-23-395.

Metalloproteinases and Their Inhibitors: Potential for the Development of New Therapeutics.

Raeeszadeh-Sarmazdeh M, Do L, Hritz B Cells. 2020; 9(5).

PMID: 32466129 PMC: 7290391. DOI: 10.3390/cells9051313.

References

Tseng T, Gross T, Celestin M, Dang W, Young L, Kao Y . Knowledge and attitudes towards low dose computed tomography lung cancer screening and smoking among African Americans-a mixed method study. Transl Cancer Res. 2022; 8(Suppl 4):S431-S442. PMC: 8797997. DOI: 10.21037/tcr.2019.04.18. View

Luna R, Horiba K, Sheppard M, Hayashi T, Fleming M, Colby T . Matrix metalloproteinases and tissue inhibitors of metalloproteinases in bronchial squamous preinvasive lesions. Hum Pathol. 2000; 31(3):296-305. DOI: 10.1016/s0046-8177(00)80242-7. View

Hart K, Landvik N, Lind H, Skaug V, Haugen A, Zienolddiny S . A combination of functional polymorphisms in the CASP8, MMP1, IL10 and SEPS1 genes affects risk of non-small cell lung cancer. Lung Cancer. 2010; 71(2):123-9. DOI: 10.1016/j.lungcan.2010.04.016. View

Yoon S, Kuivaniemi H, Gatalica Z, Olson J, Buttice G, Ye S . MMP13 promoter polymorphism is associated with atherosclerosis in the abdominal aorta of young black males. Matrix Biol. 2002; 21(6):487-98. DOI: 10.1016/s0945-053x(02)00053-7. View

Hu Z, Huo X, Lu D, Qian J, Zhou J, Chen Y . Functional polymorphisms of matrix metalloproteinase-9 are associated with risk of occurrence and metastasis of lung cancer. Clin Cancer Res. 2005; 11(15):5433-9. DOI: 10.1158/1078-0432.CCR-05-0311. View

Leeman M, Curran S, Murray G . New insights into the roles of matrix metalloproteinases in colorectal cancer development and progression. J Pathol. 2003; 201(4):528-34. DOI: 10.1002/path.1466. View

Gonzalez-Arriaga P, Pascual T, Garcia-Alvarez A, Fernandez-Somoano A, Lopez-Cima M, Tardon A . Genetic polymorphisms in MMP 2, 9 and 3 genes modify lung cancer risk and survival. BMC Cancer. 2012; 12:121. PMC: 3350430. DOI: 10.1186/1471-2407-12-121. View

Liu L, Wu J, Wu C, Wang Y, Zhong R, Zhang X . A functional polymorphism (-1607 1G→2G) in the matrix metalloproteinase-1 promoter is associated with development and progression of lung cancer. Cancer. 2011; 117(22):5172-81. DOI: 10.1002/cncr.26154. View

Stetler-Stevenson W . The role of matrix metalloproteinases in tumor invasion, metastasis, and angiogenesis. Surg Oncol Clin N Am. 2001; 10(2):383-92, x. View

10.

DerSimonian R, Laird N . Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177-88. DOI: 10.1016/0197-2456(86)90046-2. View

11.

Su L, Zhou W, Park S, Wain J, Lynch T, Liu G . Matrix metalloproteinase-1 promoter polymorphism and lung cancer risk. Cancer Epidemiol Biomarkers Prev. 2005; 14(3):567-70. DOI: 10.1158/1055-9965.EPI-04-0482. View

12.

Zhu Y, Spitz M, Lei L, Mills G, Wu X . A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter enhances lung cancer susceptibility. Cancer Res. 2001; 61(21):7825-9. View

13.

Higgins J, Thompson S . Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21(11):1539-58. DOI: 10.1002/sim.1186. View

14.

Hofmann H, Hansen G, Richter G, Taege C, Simm A, Silber R . Matrix metalloproteinase-12 expression correlates with local recurrence and metastatic disease in non-small cell lung cancer patients. Clin Cancer Res. 2005; 11(3):1086-92. View

15.

Kioi M, Yamamoto K, Higashi S, Koshikawa N, Fujita K, Miyazaki K . Matrilysin (MMP-7) induces homotypic adhesion of human colon cancer cells and enhances their metastatic potential in nude mouse model. Oncogene. 2003; 22(54):8662-70. DOI: 10.1038/sj.onc.1207181. View

16.

Biancheri P, Di Sabatino A, Corazza G, Macdonald T . Proteases and the gut barrier. Cell Tissue Res. 2012; 351(2):269-80. DOI: 10.1007/s00441-012-1390-z. View

17.

Park Y, Jung H, Ahn J, Im Y . Ets-1 upregulates HER2-induced MMP-1 expression in breast cancer cells. Biochem Biophys Res Commun. 2008; 377(2):389-394. DOI: 10.1016/j.bbrc.2008.09.135. View

18.

Vincenti M, White L, Schroen D, Benbow U, Brinckerhoff C . Regulating expression of the gene for matrix metalloproteinase-1 (collagenase): mechanisms that control enzyme activity, transcription, and mRNA stability. Crit Rev Eukaryot Gene Expr. 1996; 6(4):391-411. DOI: 10.1615/critreveukargeneexpr.v6.i4.40. View

19.

Wacholder S, Chanock S, Garcia-Closas M, El Ghormli L, Rothman N . Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst. 2004; 96(6):434-42. PMC: 7713993. DOI: 10.1093/jnci/djh075. View

20.

Begg C, Mazumdar M . Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994; 50(4):1088-101. View